Adenovirus-Induced Hemorrhagic Cystitis After CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in a Patient with Large B-Cell Lymphoma
Immunotherapy · 2023
DOI: 10.2217/imt-2023-0111 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunotherapy, 2023. Verfasst von Irene Medina und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Experimental Hematology, Vall d'Hebron Institute of Oncology, University Hospital Vall d'Hebron, 08035, Barcelona, Spain. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Lymphoma, Large B-Cell, Diffuse, Cystitis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Regeneron, Bristol Myers Squibb, Takeda and Novartis.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR) T cells targeting CD19 have changed the treatment landscape of patients with relapsed/refractory diffuse large B-cell lymphoma. Infections are one of the most frequent complications after CAR T-cell therapy. Most of these infections are bacterial, although viral infections can also occur in this setting. Adenovirus-induced hemorrhagic cystitis is a rare infectious complication and is usually observed after bone marrow or solid organ transplantation. Herein we report a case of adenovirus-induced hemorrhagic cystitis in a patient experiencing urinary symptoms within the first month after CAR T-cell infusion. Based on our experience and a literature review, we discuss the diagnostic approach and potential treatment options for this infrequent infection after CAR T-cell therapy. Lymphoma is an aggressive blood cell cancer. A treatment called chimeric antigen receptor (CAR) T-cell therapy has recently been developed for patients with lymphoma and other blood cancers. CAR T-cell therapy is based on the genetic change of the patient's T cells. T cells are a type of white blood cell, which help to attack cancer. CAR T-cell treatment is very effective, but it also carries a risk of adverse events, including infections. These infections can be caused by bacteria or viruses and can affect several organs, including the bladder. Patients with blood cancers who develop bladder infections can have severe pain and bleeding. These bleeding bladder infections are mostly caused by adenovirus or BK virus and are usually seen in patients who have received a bone marrow transplant. However, these infections are rarely observed in patients receiving CAR T cells. We report here a case of bleeding bladder infection caused by adenovirus in a patient receiving CAR T-cell therapy. We discuss the diagnostic approach and possible treatment options for this rare infection in CAR T-cell patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Experimental Hematology, Vall d'Hebron Institute of Oncology, University Hospital Vall d'Hebron, 08035, Barcelona, Spain.
- Department of Medicine, Universitat Autònoma de Barcelona, 08193, Bellaterra, Spain.
- Department of Infectious Diseases, Vall d'Hebron Research Institute, University Hospital Vall d'Hebron, 08035, Barcelona, Spain.
- Department of Hematology, Hospital Universitario Morales Meseguer, 30008, Murcia, Spain.
- Department of Microbiology, University Hospital Vall d'Hebron, 08035, Barcelona, Spain.
ORCID-Profile: Cecilia Carpio, Isabel Ruiz-Camps, Adaia Albasanz-Puig, Oriana Lopez-Godino, Juliana Esperalba, Francisco Beas, Gloria Iacoboni, Pere Barba
Förderung
- Regeneron, Bristol Myers Squibb, Takeda and Novartis
Zitieren
APA
Medina, I., Carpio, C., Ruiz-Camps, I., Albasanz-Puig, A., Lopez-Godino, O., Esperalba, J., Beas, F., Sanchez-Salinas, M., Iacoboni, G., & Barba, P. (2023). Adenovirus-Induced Hemorrhagic Cystitis After CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in a Patient with Large B-Cell Lymphoma. Immunotherapy. https://doi.org/10.2217/imt-2023-0111
Vancouver
Medina I, Carpio C, Ruiz-Camps I, Albasanz-Puig A, Lopez-Godino O, Esperalba J, et al. Adenovirus-Induced Hemorrhagic Cystitis After CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in a Patient with Large B-Cell Lymphoma. Immunotherapy. 2023. doi:10.2217/imt-2023-0111
BibTeX
@article{Medina2023,
author = {Medina, Irene and Carpio, Cecilia and Ruiz-Camps, Isabel and Albasanz-Puig, Adaia and Lopez-Godino, Oriana and Esperalba, Juliana and Beas, Francisco and Sanchez-Salinas, Mario and Iacoboni, Gloria and Barba, Pere},
title = {Adenovirus-Induced Hemorrhagic Cystitis After CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in a Patient with Large B-Cell Lymphoma},
journal = {Immunotherapy},
year = {2023},
doi = {10.2217/imt-2023-0111}
}
EUVIMED